



**MEMSCAP**  
*The Power of a Small World™*

## **MEMSCAP PAVES THE ROAD TO BREAKTHROUGH MEDICAL PROGRESS**

### *The Group chairs a project for a new biomedical sensors and implants platform*

**Grenoble, France and Skoppum, Norway, December 20, 2006** – MEMSCAP (Euronext: MEMS), the leading provider of innovative solutions based on MEMS (micro-electro-mechanical systems) technology, today announces it is chairing a new project named 'Biomedical Sensors' under the User-driven Research based Innovation (BIA) programme of The Research Council of Norway.

The main objective of the project is to create a new wired and wireless biomedical sensors platform by combining new and innovative micro sensor technology with nano/microelectronic communications technology. This solution that will consist of miniaturized MEMS chip system detecting biomedical pressure and force with unique signal processing includes new MEMS sensors, as well as in-vivo and ex-vivo wireless sensor solutions.

MEMSCAP will have the leadership and overall responsibility for this project, and will contribute to each and every step of its unfolding. Other partners in the project include Novelda AS, a Norwegian company specializing in UltraWideband (UWB) wireless technology, SINTEF ICT, the largest independent research organization in Scandinavia, and the Interventional Centre, Rikshospitalet University Hospital, a research and development centre for image guided and minimally invasive therapy at Rikshospitalet University Hospital in Oslo, Norway, where the testing of ex-vivo sensors and trials will be conducted.

The development will be based on MEMSCAP knowledge and know-how on design, development, miniaturization and manufacture of medical sensor products based on silicon MEMS technology to which will be added new wireless connectivity and integration of compensation- and analysis functionalities. The aim of this 18.9 million NOK (2.3 million euros) 3 years-project, ending on July 2009 and partly financed by The Research Council of Norway, is to offer the market a cost efficient solution.

Its numerous benefits include: reduced cost to the end user (society), either in form of payment from insurance companies and/or other financial institutions; great physical and psychological improvement of patients condition, by continuous measurements and the knowledge that their body contains a life saving monitoring system; environmental profit in the form of recirculation of plastic parts; increased quality based on systems designed for repetitive use; lower risk of faulty medication/treatment thanks to higher performance and accuracy.

With an extremely high level of innovation, this BIA project has to overcome several challenges, among which the low cost of processing and encapsulating a biocompatible, miniaturised, hermetic and robust solution for implants with the possibility for wireless communication to the outside world, or the interaction on anatomical structures and tissues.

“The BIA project is an integral part of MEMSCAP biomedical roadmap. Leveraging on our years of know-how and our unique experience in the field of medical pressure sensing, we are about to bring a new dimension to patient comfort and security.” explains Jan Hallenstvedt, General Manager of MEMSCAP Standard Products Business Unit. “The milestones of this program are the MEMS dynamometer chip, then an implantable product, qualified to relevant medical standards, and then the integration of a radio solution and a wireless excitation module in the system. We will manage the integration of the sensor platform into existing and new products in parallel with medical testing in the last phase of the project.”

#### ***About MEMSCAP***

MEMSCAP is the leading provider of innovative micro-electro-mechanical systems (MEMS)-based solutions. MEMSCAP standard and custom products and solutions include components, component designs (IP), manufacturing and related services. MEMSCAP customers include Fortune 500 businesses, major research institutes and universities. The company's shares are traded on the Eurolist of Euronext Paris S.A (ISIN: FR0010298620-MEMS), where MEMSCAP belongs to the Next Economy segment. More information on the company's products and services can be obtained at [www.memscap.com](http://www.memscap.com).

*For more information contact:*

Aurore Foulon  
Vice-President,  
Corporate Communications  
Tel. : +33 (0)4 76 92 85 00  
[aurore.foulon@memscap.com](mailto:aurore.foulon@memscap.com)

Jan Hallenstvedt  
General Manager  
Standard Products Business Unit  
Tel. : +47 33 08 40 00  
[jan.hallenstvedt@memscap.com](mailto:jan.hallenstvedt@memscap.com)